The Zacks Analyst Blog Highlights Tesla, Meta Platforms, Johnson & Johnson, Discovery, and PepsiCo
For Immediate Release
Chicago, IL – March 2, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Tesla, Inc. TSLA, Meta Platforms, Inc. FB, Johnson & Johnson JNJ, Discovery, Inc. DISCA and PepsiCo, Inc. PEP.
Here are highlights from Tuesday’s Analyst Blog:
Top Research Reports for Tesla, Meta and Johnson & Johnson
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc., Meta Platforms, Inc., and Johnson & Johnson. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Shares of Tesla have outperformed the Zacks Automotive - Domestic industry over the past year (+26.8% vs. -3.4%). Tesla put up an impressive Q4 show, outpacing both top- and bottom-line expectations. The electric vehicle (EV) leader hit an incredible milestone in Q4, with record deliveries and an all-time high gross margin. Despite the global chip crunch, Tesla's vehicle deliveries jumped 90% in 2021.
The Zacks analyst believes that increasing deliveries for Models 3 and Y is fueling the company's revenues. With China being the biggest EV market, Tesla's ambitious production plans in the country bode well. Robust production of Model 3 and Y from Shanghai gigafactory is a major positive catalyst. Along with high automotive revenues, Tesla's energy generation and storage revenues are also growing thanks to positive reception of Megapack and Powerwall products.
(You can read the full research report on Tesla here >>>)
Meta Platforms shares have declined -18.5% over the past year against the Zacks Internet - Software industry's decline of -47.1%. The Zacks analyst believes that Meta's fourth-quarter 2021 results suffered from Apple's iOS changes as well as engagement-related headwinds.
Apple's iOS changes have made ad targeting difficult, which, in turn, has increased the cost of driving outcomes. Measuring these outcomes has also become difficult. Meta expects these factors to hurt advertising growth in first-quarter and throughout 2022.
Moreover, Meta faced increased competition for people's time and a shift of engagement within its apps to video platforms like Reels, which show fewer ads than Feed or Stories, currently. Apart from ad-targeting difficulty, Meta's first-quarter guidance reflects macroeconomic and COVID-related concerns. Cost inflation and supply chain disruptions are expected to impact advertiser budgets.
(You can read the full research report on Meta Platforms here >>>)
Shares of Johnson & Johnson have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+3.5% vs. +18.3%). The Zacks analyst, however, believes that the company's Pharma unit is performing at above-market levels, supported by its blockbuster drugs, Darzalex and Stelara and contribution from newer drugs, Erleada and Tremfya and its COVID-19 vaccine.
Sales in Consumer unit are improving, withstanding external supply constraints. J&J is making rapid progress with its pipeline and line extensions. Several pivotal data readouts are expected in 2022.
Yet, the Medical Devices segment is being hurt by softening of recovery trends in medical and surgical procedures. Headwinds like generic competition and pricing pressure continue. Though J&J has taken meaningful steps to resolve its talc and opioid litigation, they continue to remain an overhang on the stock.
(You can read the full research report on Johnson & Johnson here >>>)
Other noteworthy reports we are featuring today include Discovery, Inc. and PepsiCo, Inc.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It's a little-known chemical company that's up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks' Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ) : Free Stock Analysis Report
PepsiCo, Inc. (PEP) : Free Stock Analysis Report
Discovery, Inc. (DISCA) : Free Stock Analysis Report
Tesla, Inc. (TSLA) : Free Stock Analysis Report
Meta Platforms, Inc. (FB) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
